TUDCA (tauroursodeoxycholic acid) trials recruiting now
6 registrations that name TUDCA as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 6 registrations
RecruitingNCT06025630
Targeting Endoplasmic Reticulum Stress in Human Hypertension
Phase 1 and 2
University of North Texas Health Science Center
About 70 people
Started Aug 15, 2023
In plain words A Phase 1 and 2 study of TUDCA in people 18 to 80, run by University of North Texas Health Science Center. It plans to enroll about 70 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Hypertension.
18 to 80 years of age
No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
Systolic blood pressure <140 mmHg; diastolic blood pressure <90 mmHg (obtained at the Screening and Familiarization Visit)
Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician)
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
TUDCA; Placebo
Registered summary
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.
Where, as registered
1 US site in 1 state.
RecruitingNCT07328009
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
Phase 2
Fudan University
About 350 people
Started Jan 19, 2026
In plain words A Phase 2 study of TUDCA in people 18 and older, run by Fudan University. It plans to enroll about 350 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hepato Cellular Carcinoma (HCC).
Written informed consent obtained.
Age ≥ 18 years at time of study entry.
Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/ cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients.
Patients who have previously received first-line therapy with anti-PD-1/PD-L1 combined with anti-VEGF antibodies, or anti-PD-1/PD-L1 combined with TKI, or anti-PD-1/PD-L1 combined with anti-CTLA-4 antibodies and experienced disease…
7 more inclusion criteria and the exclusion criteria are on the listing.
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure. The study aims to rapidly identify the most effective investigational regimens and discover predictive biomarker signatures (from tumor tissue, blood, and imaging) to guide personalized second-line therapy.
Where, as registered
No US site; China (1).
RecruitingNCT07100392
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Phase 2
Fudan University
About 141 people
Started Aug 14, 2025
In plain words A Phase 2 study of TUDCA in people 18 and older, run by Fudan University. It plans to enroll about 141 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hepatocellular Carcinoma (HCC).
Written informed consent obtained.
Age ≥ 18 years at time of study entry.
Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/ cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients.
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC.
7 more inclusion criteria and the exclusion criteria are on the listing.
To evaluate the efficacy and safety of Tauroursodeoxycholic Acid (TUDCA) plus Camrelizumab and Regorafenib for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07064668
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
Phase 2
Tongji Hospital
About 300 people
Starts Jul 30, 2025 (estimated)
In plain words A Phase 2 study of TUDCA in people 18 to 80, run by Tongji Hospital. It plans to enroll about 300 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Hepatocellular Carcinoma.
This is a clinical trial that aims to evaluate whether adding a bile acid called tauroursodeoxycholic acid (TUDCA) can improve the effects of immunotherapy in patients with advanced liver cancer (hepatocellular carcinoma). Immunotherapy has shown promise in treating this type of cancer, but not all patients respond well. TUDCA is known to help protect liver cells and may improve the liver's immune environment, potentially making immunotherapy more effective. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07517276
TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index
Phase 2
Peking University First Hospital
About 80 people
Starts Apr 2, 2026 (estimated)
In plain words A Phase 2 study of TUDCA in female participants 18 to 45, run by Peking University First Hospital. It plans to enroll about 80 people and lists no sites yet.
Intention to continue breastfeeding or providing expressed breast milk during the treatment period
Maternal metabolic dysfunction-associated steatotic liver disease (MASLD) defined by protocol-specified clinical criteria
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
tauroursodeoxycholic acid (TUDCA); Placebo
Registered summary
This is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial in mother-infant dyads. The study aims to evaluate the safety, tolerability, and biological effects of maternal oral tauroursodeoxycholic acid (TUDCA) in lactating mothers with metabolic dysfunction-associated steatotic liver disease (MASLD). Eligible mother-infant dyads will be screened in the early postpartum period using breast milk bile acid hydrophobicity index. Dyads identified as high risk will be randomized 1:1 to maternal oral TUDCA or placebo. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06827873
Effect of Oral Supplements for Influenza Vaccine Response
No phase
Tsinghua University
About 45 people
Starts Feb 2025 (estimated)
In plain words A study of TUDCA in people 60 to 70, run by Tsinghua University. It plans to enroll about 45 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 70; healthy volunteers accepted. Conditions: Influenza Vaccine Response.
Age 60-70 years old
Body Mass Index (BMI) 18.5-26.9 kg/m²
No influenza vaccination in the past year
Able to understand and sign the informed consent form, and capable of completing the full follow-up process
The aim of this clinical trial is to explore the efficacy of fatty acid and bile acid based supplements on enhancing influenza vaccine immune response in adults aged 60-70 years. The objectives of this study are: 1. To explore the efficacy of fatty acid and bile acid based supplements on enhancing flu vaccine immune response. 2. To evaluate the safety of fatty acid and bile acid use in elders. 3. To explore the potential role of microbiota in regulating immune response. The full summary is on the listing.